Benefit of Targeted Therapies in Metastatic Colon Cancer in the Ivorian Context
Benefit of Targeted Therapies in Metastatic Colon Cancer in the Ivorian Context作者机构：Department of Oncology University Hospital of Treichville Abidjan Cote d’Ivoire
出 版 物：《Journal of Cancer Therapy》 (癌症治疗（英文）)
年 卷 期：2017年第8卷第8期
页 面：785-792页
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
主 题：Cancer-Colon-Metastasis-Targeted Therapy
摘 要：In our daily practice, the use of targeted therapies (Bevacizumab and rarely Cetuximab) in metastatic colic cancers is recent. Very few patients benefit from these therapies because of their high cost. In a cohort of 68 patients who received these therapies, a retrospective and prospective study was conducted over three years period (1 January 2013 to 31 December 2015) to evaluate their benefit in terms of quality of life, tolerance and overall survival. These targeted therapies provided a significant clinical and biological gain with acceptable toxicities (most often resolving spontaneously). Moreover, they have allowed a significant improvement in overall survival in first line metastatic treatment. The limiting factor remains their extremely high cost and therefore inaccessibility to the majority of our patients.
维普期刊数据库